Recurrent Oral Cavity Squamous Cell Carcinoma Clinical Trials

17 clinical trials for Recurrent Oral Cavity Squamous Cell Carcinoma across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment — RECRUITING · PHASE3
• Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma — RECRUITING · PHASE1
• Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer — RECRUITING · PHASE2
• Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma — RECRUITING · PHASE2
• Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer — RECRUITING · PHASE1
• Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation — RECRUITING · NA
• TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer — RECRUITING · PHASE1
• Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial — RECRUITING · PHASE2
• Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck — ACTIVE_NOT_RECRUITING · PHASE2
• Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck — ACTIVE_NOT_RECRUITING · PHASE2
• Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery — TERMINATED · PHASE1
• Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck — COMPLETED · PHASE2
• Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer — TERMINATED · NA
• Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer — TERMINATED · PHASE2

Refine this search